Positive Data For Amgen/UCB's Romosozumab In Men With Osteoporosis

Amgen and UCB have demonstrated the efficacy of their osteoporosis treatment romosozumab in men in the Phase III BRIDGE study. This follows Phase III FRAME data in women which will form the basis of a US filing later this year.

Amgen and UCB have demonstrated the efficacy of their osteoporosis treatment romosozumab in men in the Phase III BRIDGE study. This follows Phase III FRAME data in women which will form the basis of a US filing later this year.

"While the focus of managing osteoporosis is often on women, osteoporosis in men is also a serious health issue," said...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Musculoskeletal

More from Therapy Areas

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By 

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

BioNTech To Buy mRNA Rivals CureVac

 

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By 

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?